This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C17 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the date of cancer registration) |
| B. Synonyms | Small bowel cancer, Small intestine adenocarcinoma, jejunal cancer, ileal cancer, duodenal cancer |
| C. Adult onset | Very high — mean age at diagnosis in the 60s; adenocarcinoma favors the duodenum, carcinoid the ileum |
| 1. History | Recognition of small bowel cancer as rare, early descriptions of duodenal cancer, carcinoid classification, history of the introduction of capsule endoscopy |
| 2. Causes | Crohn's disease, Peutz-Jeghers (STK11), Lynch syndrome, FAP, celiac disease, obesity, alcohol |
| 3. Genetics | STK11 (PJS), APC (FAP), MLH1 and MSH2 (Lynch), somatic KRAS, TP53, SMAD4 and APC mutations |
| 4. General epidemiology | 1–2% of all gastrointestinal cancers; about 11,000 cases per year in the US; relatively rare in Korea but increasing |
| 5. Pathophysiology | Adenoma–carcinoma sequence (duodenum), chronic inflammation in Crohn's disease, malignant change of PJS polyps, MMR deficiency |
| 6. Symptoms | Abdominal pain, bowel obstruction, weight loss, bleeding (melena), jaundice (duodenal cancer), nausea and vomiting |
| 7. Signs | Abdominal mass, jaundice, anemia, melena, elevated CEA and CA19-9, CT findings of small bowel obstruction |
| 8. Screening | No national screening; surveillance endoscopy and capsule endoscopy for PJS, Lynch and FAP hereditary syndromes |
| 9. Diagnosis | CT enterography, capsule endoscopy, double-balloon enteroscopy, upper endoscopy (duodenum), TNM staging |
| 10. Treatment | Surgical resection (Whipple, small bowel resection), FOLFOX/FOLFIRI chemotherapy, immunotherapy (MSI-H), targeted therapy |
| 11. Prognosis | Overall 5-year survival about 30–40%; localized stage 60–70%, distant metastasis 5–10% |
| 12. Prevention | Surveillance of hereditary syndromes, active management of Crohn's disease, gluten-free diet for celiac disease, smoking cessation and limiting alcohol |
| 13. References | Overman MJ et al. J Clin Oncol 2010 and 9 other papers |
The small intestine is the longest part of the human digestive tract (about 6–7 m), but malignant tumors arising in it are rare, accounting for only about 1–2% of all gastrointestinal cancers. Historical descriptions of small bowel cancer date from the 18th–19th centuries, but because the small intestine is difficult to access, diagnosis and surgery were very limited. Small bowel resection and anastomosis began to be performed from the late 19th century, and with the establishment of the Whipple operation (pancreaticoduodenectomy, 1935) in the early 20th century, curative surgery for lesions of the duodenum and adjacent small intestine became possible.
Because of the limitations of small bowel endoscopy, preoperative diagnosis of small bowel cancer was very difficult for most of the 20th century. With the clinical introduction of capsule endoscopy in 2001, the entire small bowel mucosa could be observed noninvasively, and subsequently double-balloon enteroscopy (2001) and single-balloon endoscopy were developed, making tissue biopsy possible as well. This was a revolutionary advance in the diagnosis of small bowel lesions. CT enterography also greatly improved small bowel imaging.
There have also been important advances in understanding the causes of small bowel cancer. Identification of the STK11 gene in Peutz-Jeghers syndrome (PJS) (1998), confirmation of the link between Lynch syndrome and small bowel cancer risk, and the association between Crohn's disease and small bowel adenocarcinoma were established through epidemiologic studies. Recently, MSI-H subtypes have been reported to be not uncommon in small bowel adenocarcinoma, and the potential of immune checkpoint inhibitor therapy is being explored. Carcinoid tumors (neuroendocrine tumors) also occur in the small intestine, and their prognosis has improved with the introduction of somatostatin analog therapy.
The main risk factors for small bowel cancer are hereditary syndromes and inflammatory bowel disease. Peutz-Jeghers syndrome (PJS) is caused by autosomal dominant germline mutations of the STK11 (LKB1) gene and is characterized by gastrointestinal hamartomatous polyps and mucocutaneous pigmentation (around the lips and mouth). In PJS patients, the risk of small bowel cancer is reported to be increased 520-fold compared with the general population. The cumulative risk of all gastrointestinal cancers in PJS reaches about 57% by age 65. Lynch syndrome (HNPCC) is caused by germline mutations of mismatch repair genes such as MLH1, MSH2, MSH6 and PMS2; colorectal cancer is predominant, but the risk of small bowel cancer is also increased to about 2–4%.
Familial adenomatous polyposis (FAP) is caused by germline APC mutations; besides hundreds to thousands of adenomas in the large intestine, adenomas also arise in the duodenum and periampullary region, with a risk of malignant change (Spigelman classification). Crohn's disease is reported to increase the risk of small bowel adenocarcinoma more than 20-fold compared with the general population through chronic inflammation of the small intestine. In particular, the diseased segment tends to coincide with the site where adenocarcinoma develops. Celiac disease is chronic inflammation of the small bowel mucosa caused by undigested gluten and increases the risk of enteropathy-type T-cell lymphoma and small bowel adenocarcinoma. Some associations have also been reported between small bowel cancer and alcohol, smoking, and red and processed meat intake.
Duodenal adenocarcinoma arises at the site in the gastrointestinal tract with the highest exposure to bile and pancreatic juice, and a carcinogenesis-promoting role for these digestive juices has been proposed. In addition, the unique microbial environment of the small intestine, rapid transit of contents and abundant IgA immune function are described as factors that suppress cancer development in the small intestine. This is thought to be one reason why cancer is rarer in the small intestine than in the large intestine.
The molecular genetic features of small bowel adenocarcinoma are partly similar to those of colorectal cancer but also distinct. Reported somatic alterations include KRAS (about 30–40%), TP53 (about 40–50%), SMAD4 (about 15%), APC (about 15%), ERBB2 (HER2) amplification (about 5–10%) and PIK3CA (about 10%). Duodenal and jejunal/ileal adenocarcinomas differ in their spectrum of gene alterations: FAP/APC-related alterations tend to be more common in duodenal adenocarcinoma, and Crohn's disease–related alterations in ileal adenocarcinoma.
MSI-H (microsatellite instability-high) is observed in about 15–20% of small bowel adenocarcinomas, a higher proportion than in colorectal cancer. MSI-H small bowel cancer arises from Lynch syndrome or sporadic MLH1 methylation and responds well to immune checkpoint inhibitors such as pembrolizumab. Features of small bowel cancer by hereditary syndrome: PJS is characterized by abnormalities of the AMPK and mTOR pathways due to STK11/LKB1 mutations. In FAP-related duodenal adenocarcinoma, APC mutation is central and the Spigelman stage classification is used. Lynch syndrome small bowel cancer has a high MSI-H rate and responds excellently to immunotherapy.
CDKN2A and CDKN2B deletions, FGFR alterations and NF1 mutations have also been reported rarely in small bowel adenocarcinoma. Somatic tumor mutational burden (TMB) is high in MSI-H small bowel adenocarcinoma and is used to predict response to immunotherapy. The potential of trastuzumab-targeted therapy is being explored in ERBB2 (HER2)–amplified small bowel adenocarcinoma. In small bowel neuroendocrine tumors (NETs), a different spectrum of gene alterations is observed, including MEN1, DAXX/ATRX and CDKN1B mutations.
Small bowel cancer is a rare cancer accounting for only about 1–2% of all gastrointestinal malignancies. It is unique in that cancer is uncommon even though the small intestine accounts for about 90% of the surface area of the entire gastrointestinal tract. In the United States, about 11,000 new cases of small bowel cancer are diagnosed each year: adenocarcinoma about 40%, neuroendocrine tumors (carcinoids) about 30–40%, lymphoma about 15–20%, and gastrointestinal stromal tumors (GIST) about 10%. Accurate incidence statistics for small bowel cancer in Korea are limited, but it is relatively rare and estimated at several hundred cases per year.
Distribution by site: adenocarcinoma arises in the duodenum in about 50%, the jejunum in about 25–30% and the ileum in about 20–25%. Neuroendocrine tumors (carcinoids) are most common in the ileum. Lymphoma is common in the terminal ileum. Sex and age: adenocarcinoma is slightly more common in men (male-to-female ratio about 1.3:1), and the mean age at diagnosis is in the 60s. Incidence shows a gradual upward trend in Western countries, partly due to improved diagnostic techniques (capsule endoscopy, CT enterography). The increasing prevalence of Crohn's disease also appears to contribute to the rising incidence of small bowel cancer.
The geographic distribution is less pronounced than for colorectal cancer, but high rates have been reported in Western countries and some Middle Eastern regions. The incidence of small bowel T-cell lymphoma is high in regions where celiac disease is prevalent (Middle East, North Africa). Small bowel cancer is relatively rare in Korea, but the number of diagnoses has tended to increase recently with the spread of capsule endoscopy and small bowel CT.
The pathogenesis of small bowel adenocarcinoma differs according to the underlying condition. In FAP-related duodenal adenocarcinoma, similar to Vogelstein's adenoma–carcinoma sequence in colorectal cancer, progression occurs in the order APC mutation → adenoma formation → accumulation of KRAS, TP53 and SMAD4 mutations → invasive adenocarcinoma. Around the duodenal papilla (ampulla of Vater), chronic exposure to bile and pancreatic juice causes additional mucosal damage, promoting malignant change to adenocarcinoma. In Lynch syndrome–related small bowel cancer, carcinogenesis proceeds through loss of MMR gene (MLH1, MSH2) function → inability to repair mismatches → instability of repeat sequence regions (microsatellites) → accumulation of numerous mutations. MSI-H small bowel adenocarcinoma is highly immunogenic because of the generation of numerous neoantigens.
In Crohn's disease–related small bowel cancer, the proposed sequence is chronic intestinal inflammation → chronic secretion of cytokines (IL-6, TNF-α, IL-1β) → sustained activation of the NF-κB pathway → promotion of cell proliferation and inhibition of apoptosis → dysplasia → adenocarcinoma. Adenocarcinoma tends to arise in long-standing Crohn's disease segments, especially around strictures or fistulas. In PJS-related cancer, the proposed mechanism is STK11/LKB1 mutation → loss of AMPK function → mTOR pathway hyperactivation → promotion of cell growth → polyp formation followed by malignant change. Therapeutic use of the mTOR inhibitor everolimus is being explored.
The pathogenesis of small bowel neuroendocrine tumors (NETs, carcinoids) is neoplastic transformation of Kultschitzky cells (enterochromaffin cells), with involvement of MEN1, DAXX and ATRX mutations. Carcinoid syndrome (flushing, diarrhea, wheezing) results from the secretion of vasoactive substances such as serotonin, histamine and bradykinin and appears mainly when liver metastases are present.
Small bowel cancer has few or nonspecific symptoms in the early stage, so diagnosis is often delayed. The most common symptom is abdominal pain, which varies in location and tends to worsen after meals. The pain is crampy or persistent and is caused by partial or complete bowel obstruction by the tumor. Intestinal obstruction is a common presentation of small bowel cancer, accompanied by abdominal distension, nausea, vomiting and cessation of bowel movements. Recurrent episodes of abdominal pain and vomiting suggest intermittent partial obstruction and require immediate evaluation.
Bleeding arises from the tumor surface and presents as anemia due to chronic gastrointestinal blood loss (fatigue, dizziness, pallor) or as melena (bleeding from the upper small bowel) or hematochezia (bleeding from the lower small bowel). In obscure gastrointestinal bleeding, capsule endoscopy plays a key role in detecting small bowel lesions. Weight loss and malnutrition result from reduced absorptive area and the metabolic wasting of cancer. In duodenal adenocarcinoma, jaundice (obstructive) may appear when the tumor invades the common bile duct or main pancreatic duct (periampullary region). In carcinoid tumors, carcinoid syndrome (flushing, diarrhea, wheezing, cardiac valve lesions) appears with liver metastasis. Intussusception is also an uncommon presentation caused by a polyp or tumor.
An average delay of 6–12 months from symptom onset to diagnosis is reported, which is the main factor making early detection of small bowel cancer difficult.
Physical findings of small bowel cancer also vary with the degree of progression. Early on, there are often no specific findings. A palpable abdominal mass on abdominal palpation suggests a fairly advanced lesion. Abdominal distension, hyperactive bowel sounds (partial obstruction) and tenderness around the umbilicus or in the right lower quadrant are observed. With complete obstruction, abdominal rigidity and absent bowel sounds (paralytic ileus) may occur. Jaundice (yellow skin and sclera) is a major sign of duodenal or periampullary adenocarcinoma. Scleral icterus, dark brown urine and gray stools (acholic stools) accompany it.
Blood tests show hypochromic anemia (iron deficiency, chronic gastrointestinal bleeding) and hypoalbuminemia (malnutrition), and when jaundice is present, elevated bilirubin and liver enzymes. CEA and CA19-9 may be elevated in some small bowel adenocarcinomas, but their specificity is low, so they are used for follow-up rather than diagnosis. In neuroendocrine tumors, elevated serum chromogranin A (CgA) and 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid) are characteristic markers. In PJS patients, mucocutaneous pigmentation (brown macules around the lips) is an important clinical clue. In MSI-H small bowel adenocarcinoma, loss of MMR proteins on immunohistochemistry (one or more of MLH1, MSH2, MSH6, PMS2) is confirmed.
Because small bowel cancer is rare, clinicians often mistake early symptoms for other common digestive disorders (irritable bowel syndrome, Crohn's disease flare, gastroenteritis). When abdominal pain, bleeding or weight loss appears in patients with a history of PJS, Lynch syndrome, FAP or Crohn's disease, small bowel cancer should be strongly suspected.
There is no Korean national cancer screening program for small bowel cancer, because its incidence is low and there is not yet an effective large-scale screening tool. However, systematic surveillance is needed for hereditary high-risk groups. In PJS patients, small bowel polyps are monitored by capsule endoscopy or double-balloon enteroscopy every 2–3 years from age 8, and endoscopic resection is performed when polyps are 1.5 cm or larger or symptomatic. In Lynch syndrome, the duodenum is evaluated by upper gastrointestinal endoscopy every 5 years, and CT enterography or capsule endoscopy is added if there are small bowel symptoms.
In FAP patients, surveillance of duodenal adenomas using the Spigelman classification is recommended (duodenal endoscopy every 1–5 years). For Spigelman stage IV (high risk), prophylactic duodenectomy or pancreaticoduodenectomy is considered. In patients with Crohn's disease, attention is paid to the development of small bowel cancer in long-standing segments (>10 years, strictures/fistulas), and minimizing small bowel inflammation through active medical management contributes to reducing small bowel cancer risk. In patients with celiac disease, a gluten-free diet contributes to normalization of the small bowel mucosa and to reducing the risk of small bowel lymphoma and adenocarcinoma. In obscure gastrointestinal bleeding or iron deficiency anemia, the small intestine is evaluated by capsule endoscopy.
Different methods are used to diagnose small bowel cancer depending on the location of the lesion and the clinical presentation. Duodenal adenocarcinoma can be directly observed and biopsied by upper gastrointestinal endoscopy (EGD). A side-viewing duodenoscope is particularly useful for observing periampullary and second-part (D2) duodenal lesions. For jejunal and ileal lesions, capsule endoscopy is the first-line visualization tool, followed by biopsy with double-balloon enteroscopy (DBE). DBE can evaluate the entire small intestine via the oral or anal route but is time-consuming.
CT enterography (or CT enteroclysis) is the key imaging study for evaluating the location and extent of small bowel tumors, lymph node metastasis and distant metastasis. MR enterography is also used to evaluate the small intestine without radiation exposure. PET-CT is used as a complement for detecting distant metastasis. In neuroendocrine tumors, 68Ga-DOTATATE PET-CT is very useful for detecting tumors expressing somatostatin receptors. AJCC 8th edition TNM staging: T1 (mucosa to submucosa), T2 (muscularis propria), T3 (subserosal connective tissue), T4 (invasion of visceral peritoneum or adjacent organs). N0 (no metastasis), N1 (1–3 nodes), N2 (4 or more nodes). After tissue biopsy, MMR protein IHC (MSI-H status), HER2 IHC/FISH and KRAS, RAS and BRAF mutation testing are performed.
The curative treatment for small bowel cancer is surgical resection. For duodenal adenocarcinoma, depending on the lesion location, ampullectomy, segmental duodenectomy or pancreaticoduodenectomy (Whipple operation) is performed. For jejunal and ileal adenocarcinoma, segmental small bowel resection including the tumor with regional lymphadenectomy (D2 level) is the standard. Complete resection (R0) is the most important prognostic factor. Laparoscopic or robot-assisted small bowel resection is also performed in selected cases.
Chemotherapy for metastatic or recurrent small bowel adenocarcinoma follows colorectal cancer regimens, mainly FOLFOX (5-FU + leucovorin + oxaliplatin) or FOLFIRI (5-FU + leucovorin + irinotecan). CAPOX (capecitabine + oxaliplatin) is also an option. The addition of cetuximab or bevacizumab is being explored in KRAS/RAS wild-type tumors. For MSI-H small bowel adenocarcinoma, pembrolizumab (KEYNOTE-158) or nivolumab is approved, with reported response rates of 30–40%. Trastuzumab-based therapy is being explored in HER2-positive small bowel adenocarcinoma.
In small bowel neuroendocrine tumors (G1/G2), somatostatin analogs (octreotide, lanreotide) are used as first-line treatment for symptom control and inhibition of tumor growth. Everolimus (an mTOR inhibitor) and sunitinib (a TKI) are also used in advanced small bowel NETs. With liver metastases, hepatic artery embolization (TACE) or peptide receptor radionuclide therapy (177Lu-DOTATATE, PRRT) is an option. For small bowel GIST, targeted therapy with Gleevec (imatinib) is the standard.
The prognosis of small bowel cancer varies with the stage at diagnosis and the histologic type. The overall 5-year survival rate for small bowel adenocarcinoma is about 30–40%. 5-year survival by stage: localized stage (no lymph node metastasis) about 60–70%, regional lymph node metastasis about 35–45%, and distant metastasis about 5–10%. About 30–40% have distant metastasis at diagnosis, so the overall prognosis is poor. MSI-H small bowel adenocarcinoma may have an improved prognosis owing to its excellent response to immune checkpoint inhibitors.
Small bowel neuroendocrine tumors (G1/G2) have a much better prognosis than small bowel adenocarcinoma, with 10-year survival rates reaching 60–70%. However, G3 neuroendocrine carcinoma (NEC) has a very poor prognosis. Prognostic factors include resectability (R0 resection), number of lymph node metastases, distant metastasis, histologic differentiation, MMR/MSI status, HER2 status and KRAS mutation status. Lynch syndrome–related small bowel adenocarcinoma has a high MSI-H rate and tends to have a better immunotherapy response and prognosis than sporadic disease.
Recurrence appears mainly in the peritoneum (peritoneal dissemination), liver and lungs, and local recurrence is also common. Postoperative adjuvant chemotherapy (FOLFOX, etc.) is given to high-risk patients (lymph node metastasis, T4), but evidence from established large randomized studies is still limited. Post-treatment follow-up involves CT every 3–6 months, and in patients with hereditary syndromes, surveillance of other organs (colon, uterus, ovaries, etc.) is carried out in parallel.
Prevention of small bowel cancer focuses mainly on managing high-risk hereditary syndromes and eliminating risk factors. In PJS patients, regular capsule endoscopy starting at age 8 and endoscopic resection of small bowel polyps (polypectomy) are the key preventive strategies. This allows removal of small bowel polyps before malignant change and prevention of intussusception. The effect of mTOR inhibitors (everolimus) in preventing PJS polyps is under clinical investigation. In FAP patients, surveillance of duodenal adenomas and active endoscopic treatment according to the Spigelman classification contribute to preventing duodenal adenocarcinoma. In Lynch syndrome, early detection of small bowel lesions through regular gastrointestinal surveillance endoscopy is important.
In patients with Crohn's disease, minimizing chronic small bowel inflammation through active inflammation control (biologics, immunomodulators) is recommended to lower small bowel cancer risk. Segments with strictures or long-standing Crohn's disease require periodic evaluation with the possibility of small bowel cancer in mind. In patients with celiac disease, inducing normalization of the small bowel mucosa with a strict gluten-free diet reduces the risk of small bowel lymphoma and adenocarcinoma. For prevention of small bowel cancer in the general population, limiting red and processed meat, smoking cessation, limiting alcohol and a diet rich in fresh vegetables and fruit play a supporting role. Early detection of small bowel lesions through early endoscopic evaluation of obscure gastrointestinal bleeding, iron deficiency anemia and recurrent abdominal pain is key to improving prognosis.